Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free IBRX Stock Alerts

ImmunityBio (IBRX) Financials

ImmunityBio logo
$7.79 -0.05 (-0.64%)
As of 08/21/2026 04:00 PM Eastern
Compare
Annual Income Statements for ImmunityBio

Annual Income Statements for ImmunityBio

This table shows ImmunityBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -237 -121 -96 -96 -158 -222 -347 -417 -583 -414 -351
Consolidated Net Income / (Loss)		 -237 -121 -96 -96 -160 -224 -350 -417 -584 -414 -351
Net Income / (Loss) Continuing Operations		 -237 -121 -96 -96 -160 -224 -350 -417 -584 -414 -351
Total Pre-Tax Income 		-237 -121 -97 -97 -160 -226 -350 -417 -584 -414 -352
Total Operating Income		 -239 -125 -99 -98 -156 -221 -330 -351 -362 -344 -256
Total Gross Profit		 0.24 0.04 0.05 0.05 2.20 0.61 0.93 0.24 0.62 15 113
Total Revenue		 0.24 0.04 0.05 0.05 2.20 0.61 0.93 0.24 0.62 15 113
Operating Revenue		 0.24 0.04 0.05 0.05 2.20 0.61 0.93 0.24 0.62 15 113
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.75
Operating Cost of Revenue		 - - - - - - - 0.00 0.00 0.00 0.75
Total Operating Expenses		 239 125 99 98 158 221 331 352 363 359 369
Selling, General & Admin Expense		 228 95 57 43 46 71 135 103 130 169 150
Research & Development Expense		 11 29 42 56 112 140 196 248 232 190 219
Impairment Charge		 - - - - 0.00 11 0.00 0.68 0.89 0.00 0.00
Total Other Income / (Expense), net		 1.70 3.12 2.20 1.66 -4.01 -5.15 -20 -66 -222 -69 -96
Interest Expense		 0.00 0.07 0.62 0.43 5.92 9.07 15 64 129 154 113
Interest & Investment Income		 2.99 3.10 2.67 1.86 2.44 2.44 -4.90 -15 -6.42 7.98 6.41
Other Income / (Expense), net		 -1.29 0.09 0.16 0.24 -0.53 1.49 0.19 13 -86 77 11
Income Tax Expense		 -0.30 -0.57 -0.49 -0.50 -0.11 -1.85 0.01 0.03 -0.04 0.00 -0.14
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - -2.38 -2.34 -3.06 -0.75 -0.66 -0.08 -0.07
Basic Earnings per Share		 ($3.31) ($1.47) ($1.20) ($1.22) ($0.43) ($0.59) ($0.89) ($1.04) ($1.15) ($0.59) ($0.38)
Weighted Average Basic Shares Outstanding		 71.52M 81.98M 80.58M 79.13M 366.32M 377.07M 389.23M 399.90M 508.64M 697.31M 919.86M
Diluted Earnings per Share		 ($3.31) ($1.47) ($1.20) ($1.22) ($0.43) ($0.59) ($0.89) ($1.04) ($1.15) ($0.62) ($0.38)
Weighted Average Diluted Shares Outstanding		 71.52M 81.98M 80.58M 79.13M 366.32M 377.07M 389.23M 399.90M 508.64M 700.44M 919.86M
Weighted Average Basic & Diluted Shares Outstanding		 71.52M 81.98M 80.58M 79.13M 94.21M 103.55M 397.91M 435.84M 673.95M 853.44M 1.03B

Quarterly Income Statements for ImmunityBio

This table shows ImmunityBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -233 -134 -269 -171 -59 -130 -93 -135 98 -633 -230
Consolidated Net Income / (Loss)		 -233 -134 -269 -172 -59 -130 -93 -135 98 -633 -230
Net Income / (Loss) Continuing Operations		 -233 -134 -253 -178 -59 -130 -93 -164 154 -633 -230
Total Pre-Tax Income 		-233 -134 -269 -172 -59 -130 -92 -135 98 -633 -230
Total Operating Income		 -85 -95 -199 -161 -69 -64 -71 -111 62 -70 -62
Total Gross Profit		 0.14 0.04 0.00 6.11 7.55 16 26 32 65 44 51
Total Revenue		 0.14 0.04 0.00 6.11 7.55 17 26 32 65 44 51
Operating Revenue		 0.14 0.04 - 6.11 7.55 17 26 32 - 44 51
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.06 0.14 0.35 0.07 0.24 0.30
Operating Cost of Revenue		 - 0.00 0.00 0.00 - 0.06 0.14 0.35 0.07 0.24 0.30
Total Operating Expenses		 86 95 201 173 77 81 98 175 -83 114 113
Selling, General & Admin Expense		 33 42 99 72 42 33 42 73 -40 46 52
Research & Development Expense		 52 53 102 101 35 48 55 102 -43 68 61
Total Other Income / (Expense), net		 -148 -39 -52 -11 10 -65 -21 -21 6.14 -563 -169
Interest Expense		 32 37 60 80 38 29 29 55 -2.47 28 31
Interest & Investment Income		 0.48 3.10 3.78 3.60 1.19 0.89 1.15 4.13 -0.92 2.31 3.16
Other Income / (Expense), net		 -116 -4.55 3.75 66 47 -37 6.71 30 4.60 -537 -141
Income Tax Expense		 -0.04 0.00 0.00 0.00 - -0.23 0.27 -0.04 -0.40 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.02 -0.02 -0.04 -0.05 -0.02 -0.02 -0.02 -0.04 0.03 -0.02 -0.01
Basic Earnings per Share		 ($0.37) ($0.20) ($0.20) ($0.12) ($0.07) ($0.15) ($0.10) ($0.07) ($0.06) ($0.62) ($0.22)
Weighted Average Basic Shares Outstanding		 508.64M 672.83M 686.94M 695.90M 697.31M 853.16M 888.22M 946.60M 919.86M 1.03B 1.05B
Diluted Earnings per Share		 ($0.37) ($0.20) ($0.20) ($0.14) ($0.08) ($0.15) ($0.10) ($0.07) ($0.06) ($0.62) ($0.22)
Weighted Average Diluted Shares Outstanding		 508.64M 672.83M 686.94M 697.96M 700.44M 853.16M 888.22M 946.60M 919.86M 1.03B 1.05B
Weighted Average Basic & Diluted Shares Outstanding		 673.95M 691.57M 696.53M 696.83M 853.44M 882.62M 945.25M 984.97M 1.03B 1.05B 1.06B

Annual Cash Flow Statements for ImmunityBio

This table details how cash moves in and out of ImmunityBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 117 -168 16 -7.05 -19 -41 146 -76 161 -122 -54
Net Cash From Operating Activities		 -25 -39 -49 -63 -152 -172 -274 -338 -367 -391 -305
Net Cash From Continuing Operating Activities		 -25 -39 -49 -63 -152 -172 -274 -338 -367 -391 -305
Net Income / (Loss) Continuing Operations		 -237 -121 -96 -96 -160 -224 -350 -417 -584 -414 -351
Consolidated Net Income / (Loss)		 -237 -121 -96 -96 -160 -224 -350 -417 -584 -414 -351
Depreciation Expense		 1.47 3.61 5.57 9.56 14 13 14 18 19 18 16
Amortization Expense		 0.04 2.18 1.60 0.46 - 0.79 0.47 18 42 21 -2.75
Non-Cash Adjustments To Reconcile Net Income		 210 73 38 23 6.38 23 69 50 149 -1.64 81
Changes in Operating Assets and Liabilities, net		 -0.02 3.27 2.58 0.05 -12 16 -8.18 -6.51 7.68 -15 -47
Net Cash From Investing Activities		 -175 -114 100 57 19 -20 -85 27 -30 -12 -150
Net Cash From Continuing Investing Activities		 -175 -114 100 57 19 -20 -85 27 -30 -12 -150
Purchase of Property, Plant & Equipment		 -2.24 -6.56 -35 -13 -4.29 -1.67 -34 -78 -31 -6.89 -4.25
Acquisitions		 -1.82 - - - - 0.00 0.00 -22 0.00 -1.00 0.00
Purchase of Investments		 -198 -273 -111 -95 -87 -92 -142 -34 -10 -141 -241
Sale and/or Maturity of Investments		 27 166 254 165 112 74 70 162 10 137 96
Net Cash From Financing Activities		 317 -16 -35 -0.77 114 151 505 234 558 282 400
Net Cash From Continuing Financing Activities		 317 -16 -35 -0.77 114 151 505 234 558 282 400
Repayment of Debt		 -0.13 -0.03 -20 -0.48 48 - 339 174 259 0.00 -1.13
Issuance of Debt		 - - - - - 64 0.00 0.00 193 97 2.88
Issuance of Common Equity		 316 - 1.22 0.00 30 86 166 60 110 111 401
Other Financing Activities, net		 5.81 0.32 -1.04 -0.07 39 0.67 0.98 -0.94 -3.23 73 -2.07
Effect of Exchange Rate Changes		 - - - - -0.02 -0.03 0.05 0.28 -0.29 -0.02 0.02
Cash Interest Paid		 0.00 0.07 0.67 0.48 0.02 0.04 2.11 35 77 92 71
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.02 0.00

Quarterly Cash Flow Statements for ImmunityBio

This table details how cash moves in and out of ImmunityBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 87 -132 -2.97 -18 32 -83 77 -77 28 117 -129
Net Cash From Operating Activities		 -115 -107 -100 -99 -85 -86 -80 -69 -70 -75 -66
Net Cash From Continuing Operating Activities		 -116 -107 -99 -100 -85 -86 -80 -69 -70 -75 -66
Net Income / (Loss) Continuing Operations		 -233 -134 -135 -86 -59 -130 -93 -67 -62 -633 -230
Consolidated Net Income / (Loss)		 -233 -134 -135 -86 -59 -130 -93 -67 -62 -633 -230
Depreciation Expense		 4.56 4.56 4.41 4.46 4.14 3.83 3.88 3.95 3.87 4.38 4.41
Amortization Expense		 7.00 5.06 5.44 5.62 4.98 -0.05 -0.01 -0.98 -1.70 -1.53 -2.27
Non-Cash Adjustments To Reconcile Net Income		 132 20 21 -18 -26 60 12 6.40 1.84 554 161
Changes in Operating Assets and Liabilities, net		 -26 -2.76 4.27 -6.55 -9.57 -20 -3.49 -11 -12 0.88 0.82
Net Cash From Investing Activities		 2.25 -36 -51 65 9.83 4.13 -16 -181 44 -32 -107
Net Cash From Continuing Investing Activities		 2.25 -36 -51 65 9.83 4.13 -16 -181 44 -32 -107
Purchase of Property, Plant & Equipment		 -7.96 -1.26 -0.72 -2.79 -2.11 -1.12 -1.08 -0.74 -1.31 -1.79 -3.54
Purchase of Investments		 -0.17 -48 -86 -0.75 -6.09 -0.10 -15 -181 -46 -149 -164
Sale and/or Maturity of Investments		 10 14 35 70 18 5.35 - - 90 119 60
Net Cash From Financing Activities		 201 10 149 16 107 -0.98 173 174 55 224 44
Net Cash From Continuing Financing Activities		 201 10 149 16 107 -0.98 173 174 55 224 44
Repayment of Debt		 - - - - - 0.00 - - - -0.87 -0.89
Issuance of Debt		 193 - 97 - - 0.00 - - 2.88 177 -102
Other Financing Activities, net		 -1.58 10 48 16 -0.80 -0.98 -0.33 -0.16 -0.60 48 0.34
Cash Interest Paid		 44 24 24 24 21 16 19 18 19 20 20

Annual Balance Sheets for ImmunityBio

This table presents ImmunityBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 367 317 250 182 143 221 469 362 504 383 502
Total Current Assets		 298 205 132 89 56 112 334 141 294 185 315
Cash & Equivalents		 176 8.08 24 17 16 35 181 105 265 143 88
Short-Term Investments		 118 191 104 57 36 61 136 2.54 1.01 6.38 154
Accounts Receivable		 0.22 1.09 0.15 - - 2.00 1.33 1.89 2.02 2.65 43
Inventories, net		 - - - - - - - - 0.00 8.27 0.91
Prepaid Expenses		 3.11 5.14 4.15 14 4.11 14 16 32 26 24 29
Plant, Property, & Equipment, net		 5.52 19 77 77 61 73 83 144 146 137 114
Total Noncurrent Assets		 64 93 41 16 27 37 52 78 64 61 73
Noncurrent Note & Lease Receivables		 - - - - - 6.13 6.38 6.63 6.88 7.13 7.38
Goodwill		 - - - - - - - - 17 16 14
Other Noncurrent Operating Assets		 1.36 0.79 8.83 10 25 29 43 51 39 38 51
Total Liabilities & Shareholders' Equity		 367 317 250 182 143 221 469 362 504 383 502
Total Liabilities		 11 24 32 36 22 340 713 812 1,090 871 1,001
Total Current Liabilities		 6.15 13 21 27 12 68 369 501 58 55 62
Accounts Payable		 3.44 5.80 8.23 4.49 2.24 63 67 66 53 47 54
Other Current Liabilities		 0.14 0.89 1.37 1.67 3.98 5.02 3.01 2.65 5.24 7.47 7.54
Total Noncurrent Liabilities		 4.71 12 11 8.68 11 272 344 311 1,032 816 940
Long-Term Debt		 - - - - - 254 306 241 837 746 802
Other Noncurrent Operating Liabilities		 0.00 2.27 2.00 5.95 11 17 37 70 195 70 138
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 356 293 219 146 121 -118 -244 -450 -586 -488 -500
Total Preferred & Common Equity		 356 293 219 146 121 -120 -242 -447 -587 -489 -500
Total Common Equity		 356 293 219 146 121 -120 -242 -447 -587 -489 -500
Common Stock		 607 681 718 741 783 1,495 1,720 1,931 2,375 2,885 3,197
Retained Earnings		 -250 -387 -499 -595 -662 -1,615 -1,962 -2,378 -2,962 -3,375 -3,727
Accumulated Other Comprehensive Income / (Loss)		 -0.19 -0.28 -0.38 -0.27 -0.11 0.12 0.00 0.18 0.01 1.20 29
Noncontrolling Interest		 - - - - - 1.32 -1.74 -2.49 1.05 0.97 0.90

Quarterly Balance Sheets for ImmunityBio

This table presents ImmunityBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 343 291 432 401 444 365 304 402 519 647 629
Total Current Assets		 113 67 215 196 243 163 109 208 329 453 439
Cash & Equivalents		 88 44 178 133 130 112 61 138 60 205 76
Short-Term Investments		 2.79 2.45 12 37 88 18 0.93 16 198 176 282
Accounts Receivable		 1.46 2.03 2.33 2.14 2.06 4.90 17 22 32 43 53
Inventories, net		 - - - - 1.81 1.96 8.44 6.64 6.70 0.55 1.94
Prepaid Expenses		 21 19 23 23 21 26 22 26 33 28 26
Plant, Property, & Equipment, net		 154 151 152 144 142 139 135 133 130 113 114
Total Noncurrent Assets		 76 73 65 61 60 62 59 61 60 81 75
Noncurrent Note & Lease Receivables		 6.69 6.75 6.82 6.94 7.00 7.07 7.19 7.25 7.32 0.00 0.00
Goodwill		 - - - - - 16 15 15 14 - 12
Other Noncurrent Operating Assets		 49 46 39 38 36 39 37 39 38 68 63
Total Liabilities & Shareholders' Equity		 343 291 432 401 444 365 304 402 519 647 629
Total Liabilities		 875 936 843 1,092 1,142 1,109 894 972 1,042 1,516 1,674
Total Current Liabilities		 565 613 90 54 62 61 49 51 57 68 77
Accounts Payable		 91 89 86 48 56 54 42 43 50 60 69
Other Current Liabilities		 2.84 43 4.36 6.08 6.25 7.03 7.46 7.39 7.32 7.63 7.51
Total Noncurrent Liabilities		 310 323 753 1,038 1,080 1,048 845 921 985 1,448 1,598
Long-Term Debt		 246 250 645 851 956 973 782 799 817 1,083 1,189
Other Noncurrent Operating Liabilities		 65 73 107 187 123 75 63 122 168 365 408
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -532 -645 -411 -691 -697 -744 -590 -570 -523 -869 -1,046
Total Preferred & Common Equity		 -529 -642 -412 -692 -698 -745 -591 -571 -524 -870 -1,047
Total Common Equity		 -529 -642 -412 -692 -698 -745 -591 -571 -524 -870 -1,047
Common Stock		 1,966 1,991 2,316 2,404 2,532 2,571 2,894 3,014 3,135 3,462 3,516
Retained Earnings		 -2,495 -2,633 -2,728 -3,096 -3,230 -3,316 -3,505 -3,597 -3,665 -4,359 -4,590
Accumulated Other Comprehensive Income / (Loss)		 -0.03 -0.04 0.79 -0.01 -0.01 0.10 20 13 5.00 27 27
Noncontrolling Interest		 -2.73 -3.07 1.07 1.03 1.01 0.99 0.95 0.93 0.91 0.88 0.87

Annual Metrics And Ratios for ImmunityBio

This table displays calculated financial ratios and metrics derived from ImmunityBio's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -63.18% -81.36% 2.27% 4.44% 4,585.11% -72.53% 54.38% -74.30% 159.17% 2,270.58% 668.31%
EBITDA Growth		 -4,437.17% 50.30% 22.61% 3.99% -61.96% -44.22% -53.20% 4.02% -28.01% 41.00% -1.78%
EBIT Growth		 -4,089.17% 48.20% 20.46% 0.82% -59.74% -39.93% -50.45% -2.57% -32.40% 40.37% 8.16%
NOPAT Growth		 -4,184.77% 47.88% 20.39% 0.74% -58.81% -41.36% -49.53% -6.36% -3.12% 4.99% 25.61%
Net Income Growth		 -3,729.85% 49.00% 20.19% 0.20% -66.44% -39.98% -56.05% -19.29% -39.91% 29.15% 15.03%
EPS Growth		 -341.33% 55.59% 18.37% -1.67% 64.75% -37.21% -50.85% -16.85% -10.58% 46.09% 38.71%
Operating Cash Flow Growth		 -348.03% -52.51% -26.40% -29.93% -139.99% -12.90% -59.80% -22.99% -8.67% -6.67% 22.06%
Free Cash Flow Firm Growth		 -8,311.25% 49.12% -35.52% 43.79% -60.44% -13.71% -87.46% -34.49% 61.60% 178.97% 64.39%
Invested Capital Growth		 610.36% 38.06% 424.78% 0.23% 2.08% -42.47% 12.57% 163.70% -114.17% -2,063.88% -45.25%
Revenue Q/Q Growth		 0.00% -2.22% -4.26% -9.62% 5,270.73% -79.28% 135.26% -56.91% 11.87% 101.10% 98.14%
EBITDA Q/Q Growth		 0.00% 5.38% -0.65% 8.71% -139.55% 14.13% -3.60% 6.03% -52.95% 43.58% -36.40%
EBIT Q/Q Growth		 0.00% 3.73% -0.01% 7.02% -126.41% 14.80% -3.83% 2.02% -40.60% 40.11% -28.97%
NOPAT Q/Q Growth		 0.00% 3.70% -0.25% 7.24% -125.10% 14.40% -3.73% -1.63% -0.14% 4.44% -23.05%
Net Income Q/Q Growth		 0.00% 2.09% -0.26% 6.91% -137.31% 15.60% -7.03% -4.19% -27.27% 29.64% -21.95%
EPS Q/Q Growth		 0.00% -7.30% -1.69% 6.87% 44.16% -103.45% -5.95% -2.97% -10.58% 31.87% 5.00%
Operating Cash Flow Q/Q Growth		 -47.03% 0.49% -6.29% -0.62% -151.38% 21.86% -5.39% -5.99% -7.17% 7.15% 4.62%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -17.28% 24.90% -114.94% 26.37% -20.34% 3.77% 31.19% 131.43% -56.61%
Invested Capital Q/Q Growth		 0.00% 2.31% 38.07% 1.05% -1.28% -33.94% 36.15% -3.98% -137.09% -459.85% 66.03%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.34%
EBITDA Margin		 -101,125.00% -269,597.73% -204,000.00% -187,521.28% -6,482.43% -34,026.61% -33,767.02% -126,130.83% -62,299.84% -1,550.63% -205.41%
Operating Margin		 -101,218.64% -282,954.55% -220,266.67% -209,338.30% -7,095.87% -36,509.09% -35,361.88% -146,374.17% -58,239.55% -2,334.23% -226.00%
EBIT Margin		 -101,764.83% -282,754.55% -219,917.78% -208,836.17% -7,120.12% -36,263.47% -35,341.22% -141,072.50% -72,070.10% -1,812.77% -216.69%
Profit (Net Income) Margin		 -100,371.19% -274,565.91% -214,273.33% -204,736.17% -7,273.30% -37,055.70% -37,456.96% -173,883.33% -93,866.88% -2,805.32% -310.25%
Tax Burden Percent		 99.87% 99.53% 99.49% 99.48% 99.93% 99.18% 100.00% 100.01% 99.99% 100.00% 99.96%
Interest Burden Percent		 98.76% 97.56% 97.93% 98.55% 102.22% 103.03% 105.98% 123.25% 130.25% 154.75% 143.23%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -4,565.55% -803.71% -176.60% -104.23% -163.63% -290.68% -559.89% -309.20% -512.32% 0.00% -213.79%
ROIC Less NNEP Spread (ROIC-NNEP)		 -4,532.36% -792.98% -164.13% -80.72% -87.27% -424.22% -613.22% -349.40% -570.54% 0.00% -243.61%
Return on Net Nonoperating Assets (RNNOA)		 4,454.64% 766.50% 138.95% 51.48% 43.52% -20,192.37% 752.96% 429.51% 625.06% 0.00% 284.96%
Return on Equity (ROE)		 -110.91% -37.21% -37.65% -52.75% -120.11% -20,483.05% 193.07% 120.31% 112.74% 77.02% 71.17%
Cash Return on Invested Capital (CROIC)		 -1,955.08% -835.68% -312.58% -104.46% -165.69% -236.77% -571.71% -399.22% 0.00% 0.00% -155.31%
Operating Return on Assets (OROA)		 -112.60% -36.36% -34.85% -45.40% -96.46% -120.38% -95.64% -81.46% -103.43% -60.24% -55.49%
Return on Assets (ROA)		 -111.06% -35.31% -33.96% -44.51% -98.54% -123.01% -101.36% -100.41% -134.71% -93.23% -79.44%
Return on Common Equity (ROCE)		 -110.91% -37.21% -37.65% -52.75% -120.11% -8,150.18% 192.85% 119.58% 112.58% 77.17% 71.30%
Return on Equity Simple (ROE_SIMPLE)		 -66.54% -41.17% -44.06% -65.91% -132.71% 187.12% 144.46% 93.29% 99.47% 84.57% 0.00%
Net Operating Profit after Tax (NOPAT)		 -167 -87 -69 -69 -109 -155 -231 -246 -254 -241 -179
NOPAT Margin		 -70,853.05% -198,068.18% -154,186.67% -146,536.81% -4,967.11% -25,556.36% -24,753.32% -102,461.92% -40,767.68% -1,633.96% -158.20%
Net Nonoperating Expense Percent (NNEP)		 -33.19% -10.72% -12.47% -23.51% -76.36% 133.54% 53.33% 40.20% 58.21% 49.05% 29.82%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -110.10% -101.02% 118.26% -59.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.66%
SG&A Expenses to Revenue		 96,473.73% 216,797.73% 126,935.56% 90,889.36% 2,109.72% 11,788.10% 14,481.37% 42,795.00% 20,839.23% 1,144.68% 132.41%
R&D to Revenue		 4,844.92% 66,256.82% 93,431.11% 118,548.94% 5,086.15% 23,059.01% 20,980.51% 103,395.42% 37,357.88% 1,289.55% 192.92%
Operating Expenses to Revenue		 101,318.64% 283,054.55% 220,366.67% 209,438.30% 7,195.87% 36,609.09% 35,461.88% 146,474.17% 58,339.55% 2,434.23% 325.33%
Earnings before Interest and Taxes (EBIT)		 -240 -124 -99 -98 -157 -219 -330 -339 -448 -267 -245
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -239 -119 -92 -88 -143 -206 -315 -303 -388 -229 -233
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.95 1.61 1.63 0.63 3.09 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 4.04 1.63 1.65 0.63 3.09 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 5,964.19 10,708.81 7,927.86 1,955.37 169.31 2,392.63 2,588.20 8,456.42 5,388.88 120.98 17.21
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 116.43 15.13 3.09 0.18 4.73 41.34 61.81 22.48 0.00 0.00 42.32
Enterprise Value to Revenue (EV/Rev)		 4,494.34 4,326.06 4,531.35 256.43 145.17 2,654.87 2,894.31 10,800.82 6,306.32 130.18 22.16
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.94 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.02 0.02 0.00 0.00 -2.15 -2.48 -1.50 -1.43 -0.58 -1.60
Long-Term Debt to Equity		 0.01 0.02 0.02 0.00 0.00 -2.15 -1.26 -0.54 -1.43 -0.58 -1.60
Financial Leverage		 -0.98 -0.97 -0.85 -0.64 -0.50 47.60 -1.23 -1.23 -1.10 -0.66 -1.17
Leverage Ratio		 1.00 1.05 1.11 1.19 1.22 166.52 -1.90 -1.20 -0.84 -0.83 -0.90
Compound Leverage Factor		 0.99 1.03 1.09 1.17 1.25 171.56 -2.02 -1.48 -1.09 -1.28 -1.28
Debt to Total Capital		 0.69% 1.89% 2.19% 0.00% 0.00% 187.21% 167.44% 301.40% 333.43% -139.60% 265.35%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 82.74% 193.37% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.69% 1.89% 2.19% 0.00% 0.00% 187.21% 84.70% 108.02% 333.43% -139.60% 265.35%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.97% -0.48% -1.12% 0.42% -0.48% 0.30%
Common Equity to Total Capital		 99.31% 98.11% 97.81% 100.00% 100.00% -88.18% -66.96% -200.28% -233.85% 240.08% -165.64%
Debt to EBITDA		 -0.01 -0.05 -0.05 0.00 0.00 -1.24 -1.92 -2.22 -2.16 -1.24 -3.45
Net Debt to EBITDA		 1.45 2.37 1.67 0.00 0.00 -0.76 -0.91 -1.87 -1.47 -0.59 -2.40
Long-Term Debt to EBITDA		 -0.01 -0.05 -0.05 0.00 0.00 -1.24 -0.97 -0.80 -2.16 -1.24 -3.45
Debt to NOPAT		 -0.01 -0.06 -0.07 0.00 0.00 -1.65 -2.62 -2.74 -3.30 -1.18 -4.47
Net Debt to NOPAT		 2.07 3.22 2.20 0.00 0.00 -1.02 -1.24 -2.30 -2.25 -0.56 -3.12
Long-Term Debt to NOPAT		 -0.01 -0.06 -0.07 0.00 0.00 -1.65 -1.33 -0.98 -3.30 -1.18 -4.47
Altman Z-Score		 75.65 9.47 3.22 -4.42 0.26 -10.69 -6.23 -11.97 -8.75 -12.97 -10.01
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 60.21% 0.12% 0.61% 0.14% -0.19% -0.19%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 48.40 16.34 6.35 3.26 4.82 1.64 0.91 0.28 5.05 3.36 5.10
Quick Ratio		 47.89 15.93 6.15 2.75 4.47 1.44 0.86 0.22 4.61 2.77 4.62
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -178 -91 -123 -69 -111 -126 -236 -318 -122 96 -130
Operating Cash Flow to CapEx		 -1,129.18% -588.31% -140.11% -499.46% -3,721.78% -10,289.04% -2,100.41% -431.81% -1,199.18% -5,679.97% -7,171.59%
Free Cash Flow to Firm to Interest Expense		 0.00 -1,372.98 -198.72 -159.42 -18.71 -13.88 -15.90 -5.00 -0.94 0.62 -1.16
Operating Cash Flow to Interest Expense		 0.00 -584.74 -78.93 -146.38 -25.69 -18.92 -18.48 -5.31 -2.84 -2.54 -2.71
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -684.14 -135.27 -175.68 -26.38 -19.11 -19.36 -6.54 -3.08 -2.58 -2.75
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.03 0.26
Accounts Receivable Turnover		 0.00 0.07 0.07 0.00 0.00 0.00 0.56 0.15 0.32 6.31 5.01
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16
Fixed Asset Turnover		 0.08 0.00 0.00 0.00 0.03 0.01 0.01 0.00 0.00 0.10 0.90
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Days Sales Outstanding (DSO)		 0.00 5,416.93 5,041.06 0.00 0.00 0.00 651.84 2,450.82 1,146.93 57.83 72.93
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,225.39
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24,647.68
Cash Conversion Cycle (CCC)		 0.00 5,416.93 5,041.06 0.00 0.00 0.00 651.84 2,450.82 1,146.93 57.83 -22,349.37
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 9.11 13 66 66 68 39 44 115 -16 -354 59
Invested Capital Turnover		 0.06 0.00 0.00 0.00 0.03 0.01 0.02 0.00 0.01 -0.08 1.35
Increase / (Decrease) in Invested Capital		 11 3.47 53 0.16 1.37 -29 4.88 72 -132 -337 -49
Enterprise Value (EV)		 1,061 190 204 12 320 1,606 2,703 2,592 3,923 1,919 2,510
Market Capitalization		 1,408 471 357 92 373 1,448 2,417 2,030 3,352 1,784 1,950
Book Value per Share		 $4.38 $3.56 $2.75 $1.84 $1.23 ($1.10) ($0.61) ($1.12) ($0.88) ($0.70) ($0.51)
Tangible Book Value per Share		 $4.29 $3.50 $2.72 $1.84 $1.23 ($1.12) ($0.61) ($1.17) ($0.90) ($0.72) ($0.52)
Total Capital		 358 299 224 146 121 136 362 223 251 -204 302
Total Debt		 2.47 5.65 4.91 0.00 0.00 254 606 673 837 284 802
Total Long-Term Debt		 2.47 5.65 4.91 0.00 0.00 254 306 241 837 284 802
Net Debt		 -347 -281 -153 -80 -53 157 288 565 570 135 559
Capital Expenditures (CapEx)		 2.24 6.56 35 13 4.09 1.67 13 78 31 6.89 4.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.83 -6.33 -17 -13 -7.45 -52 -53 -36 -31 -20 10
Debt-free Net Working Capital (DFNWC)		 291 193 112 62 44 44 265 72 236 130 253
Net Working Capital (NWC)		 291 193 112 62 44 44 -35 -360 236 130 253
Net Nonoperating Expense (NNE)		 70 34 27 27 51 70 119 171 330 173 172
Net Nonoperating Obligations (NNO)		 -347 -281 -153 -80 -53 157 288 565 570 135 559
Total Depreciation and Amortization (D&A)		 1.51 5.79 7.16 10 14 14 15 36 61 39 13
Debt-free, Cash-free Net Working Capital to Revenue		 -1,197.46% -14,384.09% -36,804.44% -26,887.23% -338.51% -8,674.71% -5,623.98% -14,819.58% -4,929.42% -136.77% 9.09%
Debt-free Net Working Capital to Revenue		 123,471.19% 437,709.09% 247,977.78% 130,876.60% 2,007.18% 7,203.14% 28,328.48% 29,840.42% 37,910.13% 879.23% 223.43%
Net Working Capital to Revenue		 123,471.19% 437,709.09% 247,977.78% 130,876.60% 2,007.18% 7,203.14% -3,709.64% -150,118.33% 37,910.13% 879.23% 223.43%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.31) ($1.47) ($1.20) ($1.22) ($0.70) ($0.89) ($0.89) ($1.04) ($1.15) ($0.59) ($0.38)
Adjusted Weighted Average Basic Shares Outstanding		 81.93M 82.30M 79.03M 79.09M 98.48M 109.34M 389.23M 399.90M 508.64M 697.31M 919.86M
Adjusted Diluted Earnings per Share		 ($3.31) ($1.47) ($1.20) ($1.22) ($0.70) ($0.89) ($0.89) ($1.04) ($1.15) ($0.62) ($0.38)
Adjusted Weighted Average Diluted Shares Outstanding		 81.93M 82.30M 79.03M 79.09M 98.48M 109.34M 389.23M 399.90M 508.64M 700.44M 919.86M
Adjusted Basic & Diluted Earnings per Share		 ($3.31) ($1.47) ($1.20) ($1.22) ($0.70) ($0.89) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 71.52M 81.98M 80.58M 79.13M 94.21M 103.55M 397.91M 435.84M 673.95M 853.44M 1.03B
Normalized Net Operating Profit after Tax (NOPAT)		 -167 -87 -69 -69 -109 -147 -231 -245 -253 -241 -179
Normalized NOPAT Margin		 -70,853.05% -198,068.18% -154,186.67% -146,536.81% -4,967.11% -24,322.98% -24,753.32% -102,263.29% -40,667.97% -1,633.96% -158.20%
Pre Tax Income Margin		 -100,498.73% -275,865.91% -215,368.89% -205,806.38% -7,278.07% -37,360.83% -37,456.00% -173,869.17% -93,873.31% -2,805.32% -310.37%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -1,885.03 -160.13 -226.68 -26.48 -24.18 -22.23 -5.33 -3.47 -1.73 -2.18
NOPAT to Interest Expense		 0.00 -1,320.45 -112.27 -159.06 -18.48 -17.04 -15.57 -3.87 -1.96 -1.56 -1.59
EBIT Less CapEx to Interest Expense		 0.00 -1,984.42 -216.47 -255.99 -27.17 -24.36 -23.11 -6.56 -3.71 -1.78 -2.22
NOPAT Less CapEx to Interest Expense		 0.00 -1,419.85 -168.61 -188.37 -19.17 -17.22 -16.45 -5.10 -2.20 -1.61 -1.63
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -2.03% -13.12% -15.79% -0.24% -1.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for ImmunityBio

This table displays calculated financial ratios and metrics derived from ImmunityBio's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 1,028,111,456.00 1,047,353,977.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 1,028,111,456.00 1,047,353,977.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.62 -0.22
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 90.41% -88.89% 2,453.66% 7,346.34% 5,333.09% 41,192.50% 0.00% 425.07% 652.53% 167.64% 93.91%
EBITDA Growth		 -239.15% -30.84% -3.09% 14.18% 92.81% -8.89% 32.31% 7.40% -47.37% -515.20% -229.74%
EBIT Growth		 -178.89% -17.20% 4.42% 20.37% 88.71% -2.19% 33.74% 14.12% -45.21% -495.20% -213.29%
NOPAT Growth		 -0.58% 14.68% -16.66% -0.15% 18.72% 32.32% 28.24% 30.68% -43.29% -8.32% 13.45%
Net Income Growth		 -115.47% -15.05% 2.63% 10.34% 74.65% 3.33% 31.21% 21.55% -39.26% -388.02% -148.87%
EPS Growth		 -42.31% 25.93% 37.50% 26.32% 78.38% 25.00% 50.00% 50.00% 25.00% -313.33% -120.00%
Operating Cash Flow Growth		 -27.05% -26.89% -25.79% -13.00% 26.14% 19.70% 20.53% 30.23% 17.34% 12.28% 16.62%
Free Cash Flow Firm Growth		 154.87% 140.43% -1,080.82% -653.00% 301.45% -594.01% 3.86% 90.78% 869.35% 240.47% 390.79%
Invested Capital Growth		 -114.17% -111.76% 2.21% 123.03% -2,063.88% 1,283.77% 84.96% -63.64% -45.25% -238.69% -382.46%
Revenue Q/Q Growth		 69.51% -71.22% 2,517.50% 483.19% 23.68% 118.71% -100.00% 0.00% 101.83% -31.69% 15.91%
EBITDA Q/Q Growth		 -338.59% 52.63% 2.79% 57.51% 63.28% -617.91% -27.65% 37.52% 188.14% -975.18% 66.85%
EBIT Q/Q Growth		 -239.75% 50.58% 2.29% 51.46% 51.82% -347.18% -26.71% 37.09% 182.26% -1,007.75% 66.65%
NOPAT Q/Q Growth		 -6.56% -11.49% -4.35% 19.21% 13.52% 7.16% -121.28% 21.96% 180.24% -178.18% 11.60%
Net Income Q/Q Growth		 -144.05% 42.54% -0.34% 36.28% 30.99% -119.11% -42.79% 27.33% 172.75% -746.44% 63.59%
EPS Q/Q Growth		 -94.74% 45.95% 0.00% 30.00% 42.86% -87.50% 33.33% 30.00% 14.29% -933.33% 64.52%
Operating Cash Flow Q/Q Growth		 -31.88% 7.19% 6.20% 1.58% 13.79% -0.89% 7.17% 13.59% -2.13% -7.08% 11.76%
Free Cash Flow Firm Q/Q Growth		 260.21% -47.63% -287.02% -56.74% 361.49% -164.45% 27.66% 88.58% 825.93% 134.30% -5.79%
Invested Capital Q/Q Growth		 -137.09% 32.82% 472.66% 140.19% -459.85% 136.75% -41.77% -52.78% 66.03% -403.81% -18.58%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 99.65% 0.00% 98.90% 99.89% 99.46% 99.42%
EBITDA Margin		 -136,871.22% -225,322.50% -8,367.91% -609.71% -181.02% -594.21% 0.00% -244.14% 106.61% -1,365.84% -390.64%
Operating Margin		 -61,430.94% -237,990.00% -9,487.39% -1,314.33% -918.96% -390.08% 0.00% -347.03% 96.17% -157.88% -120.41%
EBIT Margin		 -145,188.49% -249,355.00% -9,308.12% -774.70% -301.80% -617.07% 0.00% -253.41% 103.27% -1,372.30% -394.81%
Profit (Net Income) Margin		 -167,923.74% -335,325.00% -12,854.25% -1,404.39% -783.62% -785.05% 0.00% -419.66% 151.27% -1,431.47% -449.63%
Tax Burden Percent		 99.98% 100.00% 100.00% 100.00% 100.00% 99.82% 100.29% 99.95% 100.38% 100.00% 100.00%
Interest Burden Percent		 115.68% 134.48% 138.10% 181.28% 259.65% 127.45% 142.94% 165.69% 145.93% 104.31% 113.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.41% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -540.40% -1,222.06% -214.69% -94.81% 0.00% -143.34% 0.00% -207.35% 130.50% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -571.00% -1,232.41% -223.83% -99.37% 0.00% -155.41% 0.00% -215.43% 136.63% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 625.58% 1,315.40% 237.33% 111.62% 0.00% 169.84% 0.00% 238.20% -159.83% 0.00% 0.00%
Return on Equity (ROE)		 85.18% 93.34% 22.63% 16.80% 77.02% 26.50% 0.00% 30.86% -29.32% 117.10% 122.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -625.11% -430.53% 0.00% -277.30% -368.70% -124.10% -155.31% 0.00% 0.00%
Operating Return on Assets (OROA)		 -208.37% -202.41% -33.10% -14.25% -10.03% -54.70% 0.00% -32.80% 26.45% -407.12% -127.03%
Return on Assets (ROA)		 -241.00% -272.20% -45.72% -25.84% -26.04% -69.59% 0.00% -54.31% 38.74% -424.68% -144.67%
Return on Common Equity (ROCE)		 85.06% 93.21% 22.60% 16.83% 77.17% 26.54% 0.00% 30.90% -29.38% 117.25% 122.99%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 86.91% 85.59% 78.89% 0.00% 69.18% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -60 -67 -70 -56 -49 -45 -100 -78 62 -49 -43
NOPAT Margin		 -43,001.65% -166,593.00% -6,641.17% -920.03% -643.27% -273.05% 0.00% -242.92% 96.57% -110.51% -84.29%
Net Nonoperating Expense Percent (NNEP)		 30.60% 10.34% 9.14% 4.56% 3.01% 12.08% 12.34% 8.09% -6.13% 82.87% 25.34%
Return On Investment Capital (ROIC_SIMPLE)		 -23.81% - - - 23.85% -23.55% -43.52% -26.53% 20.68% -22.88% -30.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.35% 0.00% 1.10% 0.11% 0.54% 0.58%
SG&A Expenses to Revenue		 23,820.14% 104,712.50% 4,704.01% 588.21% 552.58% 197.70% 0.00% 226.33% -61.65% 103.54% 101.14%
R&D to Revenue		 37,073.38% 133,377.50% 4,883.38% 826.12% 466.38% 292.03% 0.00% 319.59% -65.85% 153.80% 118.69%
Operating Expenses to Revenue		 61,530.94% 238,090.00% 9,587.39% 1,414.33% 1,018.96% 489.73% 0.00% 545.92% -127.50% 257.34% 219.83%
Earnings before Interest and Taxes (EBIT)		 -202 -100 -97 -47 -23 -102 -129 -81 67 -607 -202
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -190 -90 -88 -37 -14 -98 -125 -78 69 -604 -200
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 5,388.88 11,983.85 3,341.52 353.40 120.98 82.28 74.63 40.67 17.21 55.94 55.31
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 124.93 34.96 0.00 25.32 39.34 80.76 42.32 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 6,306.32 14,238.94 3,906.73 468.43 130.18 105.38 95.33 50.46 22.16 60.83 60.33
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 19.94 0.00 0.00 0.00 0.00 67.44 88.45
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.43 -1.23 -1.37 -1.31 -0.58 -1.32 -1.40 -1.56 -1.60 -1.25 -1.14
Long-Term Debt to Equity		 -1.43 -1.23 -1.37 -1.31 -0.58 -1.32 -1.40 -1.56 -1.60 -1.25 -1.14
Financial Leverage		 -1.10 -1.07 -1.06 -1.12 -0.66 -1.09 -1.09 -1.11 -1.17 -0.97 -0.91
Leverage Ratio		 -0.84 -0.61 -0.55 -0.69 -0.83 -0.55 -0.67 -0.70 -0.90 -0.65 -0.64
Compound Leverage Factor		 -0.97 -0.82 -0.76 -1.25 -2.15 -0.70 -0.95 -1.15 -1.31 -0.68 -0.73
Debt to Total Capital		 333.43% 533.17% 369.38% 425.51% -139.60% 408.31% 348.49% 278.31% 265.35% 506.97% 827.87%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 333.43% 533.17% 369.38% 425.51% -139.60% 408.31% 348.49% 278.31% 265.35% 506.97% 827.87%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.42% 0.65% 0.39% 0.43% -0.48% 0.50% 0.41% 0.31% 0.30% 0.41% 0.60%
Common Equity to Total Capital		 -233.85% -433.81% -269.77% -325.94% 240.08% -308.81% -248.89% -178.62% -165.64% -407.38% -728.47%
Debt to EBITDA		 -2.16 -2.08 -2.32 -2.40 -1.24 -3.30 -4.52 -4.79 -3.45 -1.47 -1.36
Net Debt to EBITDA		 -1.47 -1.66 -1.79 -2.08 -0.59 -3.04 -3.65 -3.28 -2.40 -0.93 -0.95
Long-Term Debt to EBITDA		 -2.16 -2.08 -2.32 -2.40 -1.24 -3.30 -4.52 -4.79 -3.45 -1.47 -1.36
Debt to NOPAT		 -3.30 -3.51 -3.79 -3.86 -1.18 -3.56 -4.44 -5.61 -4.47 -5.92 -6.75
Net Debt to NOPAT		 -2.25 -2.81 -2.93 -3.34 -0.56 -3.28 -3.58 -3.84 -3.12 -3.77 -4.72
Long-Term Debt to NOPAT		 -3.30 -3.51 -3.79 -3.86 -1.18 -3.56 -4.44 -5.61 -4.47 -5.92 -6.75
Altman Z-Score		 -7.13 -9.22 -8.11 -11.40 -10.86 -15.20 -11.60 -8.32 -7.96 -8.48 -7.04
Noncontrolling Interest Sharing Ratio		 0.14% 0.14% 0.15% -0.18% -0.19% -0.15% 0.00% -0.15% -0.19% -0.13% -0.11%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.05 3.64 3.91 2.68 3.36 2.22 4.11 5.77 5.10 6.67 5.72
Quick Ratio		 4.61 3.21 3.54 2.22 2.77 1.61 3.48 5.07 4.62 6.24 5.36
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 72 38 -70 -110 289 -186 -135 -15 112 261 246
Operating Cash Flow to CapEx		 -1,449.04% -8,483.90% -13,860.08% -3,537.36% -4,033.35% -7,663.25% -7,377.06% -9,299.19% -5,376.47% -4,217.07% -1,878.89%
Free Cash Flow to Firm to Interest Expense		 2.24 1.00 -1.80 -2.74 7.68 -6.44 -4.35 -0.28 0.00 9.18 7.88
Operating Cash Flow to Interest Expense		 -3.59 -2.85 -2.57 -2.45 -2.27 -2.98 -2.58 -1.25 0.00 -2.65 -2.13
Operating Cash Flow Less CapEx to Interest Expense		 -3.84 -2.89 -2.59 -2.52 -2.32 -3.01 -2.61 -1.26 0.00 -2.71 -2.24
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.02 0.03 0.09 0.07 0.13 0.26 0.30 0.32
Accounts Receivable Turnover		 0.32 0.17 0.64 2.03 6.31 3.19 2.56 3.10 5.01 4.64 4.37
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.16 0.16 0.21 0.26
Fixed Asset Turnover		 0.00 0.00 0.01 0.05 0.10 0.22 0.23 0.43 0.90 1.14 1.34
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.02 0.02
Days Sales Outstanding (DSO)		 1,146.93 2,176.10 569.96 179.94 57.83 114.51 142.57 117.90 72.93 78.61 83.47
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 4,673.66 2,310.87 2,225.39 1,758.69 1,430.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 281,370.95 54,812.49 27,680.50 24,647.68 19,965.66 18,745.17
Cash Conversion Cycle (CCC)		 1,146.93 2,176.10 569.96 179.94 57.83 -281,256.44 -49,996.27 -25,251.73 -22,349.37 -18,128.35 -17,231.70
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -16 -11 41 98 -354 130 76 36 59 -180 -214
Invested Capital Turnover		 0.01 0.01 0.03 0.10 -0.08 0.52 0.54 0.85 1.35 -5.61 -2.40
Increase / (Decrease) in Invested Capital		 -132 -104 0.89 54 -337 141 35 -63 -49 -310 -289
Enterprise Value (EV)		 3,923 4,300 5,110 3,434 1,919 3,290 2,977 2,885 2,510 8,575 10,003
Market Capitalization		 3,352 3,619 4,371 2,591 1,784 2,569 2,330 2,325 1,950 7,886 9,170
Book Value per Share		 ($0.88) ($1.03) ($1.01) ($1.07) ($0.70) ($0.69) ($0.65) ($0.55) ($0.51) ($0.85) ($1.00)
Tangible Book Value per Share		 ($0.90) ($1.05) ($1.03) ($1.09) ($0.72) ($0.71) ($0.66) ($0.57) ($0.52) ($0.85) ($1.01)
Total Capital		 251 160 259 229 -204 192 229 294 302 214 144
Total Debt		 837 851 956 973 284 782 799 817 802 1,083 1,189
Total Long-Term Debt		 837 851 956 973 284 782 799 817 802 1,083 1,189
Net Debt		 570 680 738 842 135 720 645 559 559 689 832
Capital Expenditures (CapEx)		 7.96 1.26 0.72 2.79 2.11 1.12 1.08 0.74 1.31 1.79 3.54
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -31 -29 -37 -28 -20 -1.63 3.83 15 10 4.12 4.88
Debt-free Net Working Capital (DFNWC)		 236 142 181 102 130 60 157 272 253 385 362
Net Working Capital (NWC)		 236 142 181 102 130 60 157 272 253 385 362
Net Nonoperating Expense (NNE)		 174 67 65 30 11 85 85 57 -35 584 187
Net Nonoperating Obligations (NNO)		 570 680 738 842 135 720 645 559 559 689 832
Total Depreciation and Amortization (D&A)		 12 9.61 9.84 10 9.12 3.78 3.87 2.97 2.16 2.85 2.14
Debt-free, Cash-free Net Working Capital to Revenue		 -4,929.42% -9,447.68% -2,848.55% -384.30% -136.77% -5.23% 12.27% 25.45% 9.09% 2.92% 2.94%
Debt-free Net Working Capital to Revenue		 37,910.13% 47,007.62% 13,816.51% 1,393.75% 879.23% 192.04% 504.41% 476.35% 223.43% 273.09% 218.50%
Net Working Capital to Revenue		 37,910.13% 47,007.62% 13,816.51% 1,393.75% 879.23% 192.04% 504.41% 476.35% 223.43% 273.09% 218.50%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.37) ($0.20) ($0.20) ($0.12) ($0.07) ($0.15) ($0.10) ($0.07) ($0.06) ($0.62) ($0.22)
Adjusted Weighted Average Basic Shares Outstanding		 508.64M 672.83M 686.94M 695.90M 697.31M 853.16M 888.22M 946.60M 919.86M 1.03B 1.05B
Adjusted Diluted Earnings per Share		 ($0.37) ($0.20) ($0.20) ($0.14) ($0.08) ($0.15) ($0.10) ($0.07) ($0.06) ($0.62) ($0.22)
Adjusted Weighted Average Diluted Shares Outstanding		 508.64M 672.83M 686.94M 697.96M 700.44M 853.16M 888.22M 946.60M 919.86M 1.03B 1.05B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 673.95M 691.57M 696.53M 696.83M 853.44M 882.62M 945.25M 984.97M 1.03B 1.05B 1.06B
Normalized Net Operating Profit after Tax (NOPAT)		 -60 -67 -70 -56 -49 -45 -100 -78 44 -49 -43
Normalized NOPAT Margin		 -43,001.65% -166,593.00% -6,641.17% -920.03% -643.27% -273.05% 0.00% -242.92% 67.32% -110.51% -84.29%
Pre Tax Income Margin		 -167,952.52% -335,325.00% -12,854.25% -1,404.39% -783.62% -786.46% 0.00% -419.88% 150.70% -1,431.45% -449.63%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -6.28 -2.66 -2.50 -1.18 -0.61 -3.53 -4.17 -1.47 0.00 -21.31 -6.47
NOPAT to Interest Expense		 -1.86 -1.78 -1.78 -1.40 -1.29 -1.56 -3.22 -1.41 0.00 -1.72 -1.38
EBIT Less CapEx to Interest Expense		 -6.53 -2.69 -2.52 -1.24 -0.66 -3.57 -4.21 -1.49 0.00 -21.38 -6.59
NOPAT Less CapEx to Interest Expense		 -2.11 -1.81 -1.80 -1.47 -1.35 -1.60 -3.26 -1.43 0.00 -1.78 -1.50
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ImmunityBio (NASDAQ: IBRX) continues to look like a development-stage biotech with meaningful revenue growth, but the financial profile is still dominated by heavy losses, large debt, and frequent equity issuance. Over the past several years, the company has moved from very limited revenue to a more material quarterly revenue base, but it has not yet translated that into consistent profitability or positive operating cash flow.

Top-line trend: Revenue has generally improved compared with 2023 and early 2024. In Q1 2026, the company reported $44.2 million in revenue, up from $32.1 million in Q3 2025 and well above the near-zero levels seen in 2023. Q4 2025 revenue was also strong at $64.7 million. That said, revenue remains lumpy quarter to quarter, which is common for biotech companies with limited commercial scale.

Profitability trend: The company is still losing a lot of money. In Q1 2026, net loss attributable to common shareholders was $632.8 million, driven in part by $536.8 million of other expense. Even in stronger quarters like Q4 2025, ImmunityBio posted a profit on paper, but the business has not shown durable earnings power. Operating expenses remain high, with Q1 2026 operating expenses of $113.8 million versus gross profit of only $44.0 million.

Cash flow trend: Operating cash flow remains negative. In Q1 2026, operating cash flow was negative $75.4 million, compared with negative $70.4 million in Q4 2025 and negative $68.9 million in Q3 2025. The company is still burning cash from operations, even though financing and investment activity have at times offset the drain.

Balance sheet and liquidity: ImmunityBio ended Q1 2026 with $205.2 million in cash and equivalents plus $175.7 million in short-term investments, for roughly $381 million of liquid assets. That is a meaningful cushion. However, total debt is very large at $1.08 billion in long-term debt, and total liabilities were $1.52 billion versus negative equity of $870.0 million. The balance sheet remains highly leveraged.

  • Revenue has grown meaningfully from the tiny levels seen in 2023 to tens of millions per quarter in 2025 and 2026.
  • Liquidity remains relatively strong with about $381 million in cash and short-term investments at the end of Q1 2026.
  • Productive investment assets are present, including $112.8 million in net property and equipment, which suggests an operating footprint beyond pure R&D.
  • Quarterly results are volatile, with revenue, profit, and cash flow swinging significantly from quarter to quarter.
  • The company continues to rely on external financing, including debt issuance and equity issuance in prior quarters to fund operations.
  • Weighted average shares outstanding have increased over time, which can dilute existing shareholders.
  • Operating cash flow is still negative, indicating the core business is not yet self-funding.
  • Debt is very high at more than $1.0 billion, creating meaningful financial risk.
  • Equity remains deeply negative, reflecting accumulated losses and a strained balance sheet.
  • Net losses remain substantial, and Q1 2026 included a very large other expense item that worsened results dramatically.

Bottom line: ImmunityBio has clearly made progress on revenue generation, but investors should not overlook the fact that the company is still operating with large losses, negative operating cash flow, and a heavily leveraged balance sheet. For retail investors, this remains a high-risk biotech story where commercial growth matters, but financial stability is still a major question.

08/23/26 06:15 AM ETAI Generated. May Contain Errors.

ImmunityBio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ImmunityBio's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ImmunityBio's net income appears to be on an upward trend, with a most recent value of -$351.47 million in 2025, rising from -$236.88 million in 2015. The previous period was -$413.65 million in 2024. See ImmunityBio's forecast for analyst expectations on what's next for the company.

ImmunityBio's total operating income in 2025 was -$256.03 million, based on the following breakdown:
  • Total Gross Profit: $112.54 million
  • Total Operating Expenses: $368.56 million

Over the last 10 years, ImmunityBio's total revenue changed from $236 thousand in 2015 to $113.29 million in 2025, a change of 47,903.4%.

ImmunityBio's total liabilities were at $1.00 billion at the end of 2025, a 15.0% increase from 2024, and a 9,126.8% increase since 2015.

In the past 10 years, ImmunityBio's cash and equivalents has ranged from $8.08 million in 2016 to $265.45 million in 2023, and is currently $88.33 million as of their latest financial filing in 2025.

Over the last 10 years, ImmunityBio's book value per share changed from 4.38 in 2015 to -0.51 in 2025, a change of -111.6%.


Related Companies

Financial statements for NASDAQ:IBRX last updated on 8/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel